

Relationships With Industry and Other Entities (Comprehensive)—2017 ACC Expert Consensus Decision Pathway on Optimization of Heart Failure Treatment: *Answers to 10 pivotal questions about heart failure with reduced ejection fraction*

Committee Member	Employment	Consultant	Speakers Bureau	Ownership/ Partnership / Principal	Personal Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
Clyde W. Yancy (Chair)	Northwestern University, Feinberg School of Medicine— Vice Dean, Diversity & Inclusion; Magerstadt Professor of Medicine; Chief Division of Cardiology	None	None	None	None	• JAMA Cardiology— Deputy Editor†	None
James L. Januzzi Jr.(Vice Chair)	Massachusetts General Hospital— Professor of Medicine, Harvard Medical School	<ul style="list-style-type: none"> • Critical Diagnostics† • Novartis† • Philips • Roche Diagnostics† • Sphingotec† 	None	None	<ul style="list-style-type: none"> • Amgen (DSMB) • Boeringer Ingelheim (DSMB)† • Jansen Pharmaceuticals (DSMB) • Prevencio† 	None	
Larry A. Allen	University of Colorado School of Medicine— Associate Professor of Medicine	<ul style="list-style-type: none"> • Amgen • Janseen Scientific Affairs • Johnson and Johnson • Medscape • Novartis† • St. Jude • WebMD • ZS Pharma 	None	None	<ul style="list-style-type: none"> • American Heart Association† • NIH NHLBI† • PCORI† 	<ul style="list-style-type: none"> • Boettcher Foundation— Trustee* • Janssen‡ • Johnson & Johnson‡ • Thoratec‡ 	None
Javed Butler	Stony Brook University School of Medicine— Professor of Medicine	<ul style="list-style-type: none"> • Bayer† • Boehringer Ingelheim† • CardioCell† • CVRx • Gilead • Janssen • Medtronic • Merck† • Novartis† • PharmaIN • Relypsa† • Stealth Peptide • Tekeda* 	<ul style="list-style-type: none"> • Novartis† 	None	<ul style="list-style-type: none"> • Amgen (DSMB)† • Bristol-Myers Squibb (DSMB) • European Union† • NIH† 	<ul style="list-style-type: none"> • American Heart Association† • American Heart Journal* • European Journal of Heart Failure* • Heart Failure Society of America* • Medscape • NIH‡ 	None

Committee Member	Employment	Consultant	Speakers Bureau	Ownership/ Partnership / Principal	Personal Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
		<ul style="list-style-type: none"> • Z Pharma 					
Leslie L. Davis	University of North Carolina, Greensboro— Associate Professor of Nursing	None	None	None	None	<ul style="list-style-type: none"> • American Society of Hypertension 	None
Gregg C. Fonarow	David Geffen School of Medicine, UCLA Division of Cardiology — Professor of Medicine	<ul style="list-style-type: none"> • Amgen • Janssen • Medtronic • Novartis† • St. Jude • ZS Pharma 	None	None	<ul style="list-style-type: none"> • Medtronic • NHLBI† • NIH/NIAID† • Novartis† 	<ul style="list-style-type: none"> • American Heart Association* • JAMA Cardiology— Associate Editor* • Medtronic* 	None
Nasrien E. Ibrahim	Massachusetts General Hospital—Clinical Research Fellow	None	None	None	None	None	None
Mariell Jessup	Fondation Leducq— Chief Scientific Officer	None	None	None	None	<ul style="list-style-type: none"> • UpToDate— Editor • ABIM* 	None
JoAnn Lindenfeld	Vanderbilt University— Director, Heart Failure and Transplantation Program	<ul style="list-style-type: none"> • Abbott • Boston Scientific • Cardiomems† • CVRx • Jaansen • Novartis • Relypsa† • RESMED† 	None	None	<ul style="list-style-type: none"> • AstraZeneca* • Novartis† 	<ul style="list-style-type: none"> • AstraZeneca‡ • St. Jude† 	None
Thomas M. Maddox	VA Eastern Colorado Health Care System, University of Colorado School of Medicine— National Director, VA CART Program	None	<ul style="list-style-type: none"> • Creative Educational Concepts CME† 	None	None	None	None
Shweta R. Motiwala	Brigham and Women's Hospital— Heart Failure/Transplant Fellow	None	None	None	None	None	None
J. Herbert Patterson	UNC Eshelman School of Pharmacy— Professor of Pharmacy and Research; Professor of Medicine	<ul style="list-style-type: none"> • Novartis† 	None	None	<ul style="list-style-type: none"> • Amgen* • Novartis* • Otsuka America* 	None	None

Committee Member	Employment	Consultant	Speakers Bureau	Ownership/ Partnership / Principal	Personal Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
Mary Norine Walsh	St. Vincent Heart Center of Indiana— Medical Director, Heart Failure and Cardiac Transplantation	None	None	None	None	<ul style="list-style-type: none"> • Corvia Medical‡ • Otsuka‡ • PCORI‡ • Thoratec‡ 	None
Alan Gary Wasserman	The George Washington University School of Medicine and Health Sciences—Eugene Meyer Professor of Medicine Chairman, Department of Medicine	None	None	None	None	None	<ul style="list-style-type: none"> • Defendant, workers comp, 2016

This table represents ALL relationships of committee members with industry and other entities that were reported by authors, including those not deemed to be relevant to this document, at the time this document was under development. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of $\geq 5\%$ of the voting stock or share of the business entity, or ownership of $\geq \$5,000$ of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Please refer to <http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy> for definitions of disclosure categories or additional information about the ACC Disclosure Policy for Writing Committees.

* No financial benefit.

† Significant relationship

‡ This disclosure was entered under the Clinical Trial Enroller category in the ACC's disclosure system. To appear in this category, the author acknowledges that there is no direct or institutional relationship with the trial sponsor as defined in the ACC Disclosure Policy for Writing Committees